Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal concentration range of golimumab in patients with axial spondyloarthritis.
Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D. Martínez-Feito A, et al. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15. Clin Exp Rheumatol. 2018. PMID: 28980904
Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.
Hernández-Breijo B, Jurado T, Rodríguez-Martín E, Martínez-Feito A, Plasencia-Rodríguez C, Balsa A, Alonso-Pacheco ML, Villar LM, Herranz-Pinto P, Pascual-Salcedo D. Hernández-Breijo B, et al. Br J Dermatol. 2018 Sep;179(3):765-766. doi: 10.1111/bjd.16537. Epub 2018 Jun 21. Br J Dermatol. 2018. PMID: 29526036 No abstract available.
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MÁ, Monjo I, Nuño L, Nozal P, Pascual-Salcedo D, Balsa A. Martínez-Feito A, et al. Clin Rheumatol. 2019 Mar;38(3):949-954. doi: 10.1007/s10067-018-4355-0. Epub 2018 Nov 6. Clin Rheumatol. 2019. PMID: 30402698
Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A. Hernández-Breijo B, et al. Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3. Arthritis Res Ther. 2019. PMID: 30786913 Free PMC article.
Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.
Martínez Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, Nozal P, Ángeles González M, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A. Martínez Feito A, et al. Semin Arthritis Rheum. 2020 Feb;50(1):E1-E2. doi: 10.1016/j.semarthrit.2019.06.021. Epub 2019 Jun 28. Semin Arthritis Rheum. 2020. PMID: 31375255 No abstract available.
Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis.
Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Jochems A, Hernández-Breijo B, Peiteado D, Tornero C, Pascual-Salcedo D, Balsa A. Martínez-Feito A, et al. Scand J Clin Lab Invest. 2019 Nov;79(7):538-540. doi: 10.1080/00365513.2019.1669813. Epub 2019 Sep 27. Scand J Clin Lab Invest. 2019. PMID: 31561717 No abstract available.
60 results